Details

Autor(en) / Beteiligte

• Borel, Cecile
• Dastugue, Nicole
• Cances-Lauwers, Valérie
• Mozziconacci, Marie-Joelle
• Prebet, Thomas
• Vey, Norbert
• Pigneux, Aranud
• Lippert, Eric
• Visanica, Sorin
• Legrand, Faezeh
• Rault, Jean Philippe
• Taviaux, Sylvie
• Bastard, Christian
• Mugneret, Francine
• Collonges Rames, Marie Agnes
• Gachard, Nathalie
• Talmant, Pascaline
• Delabesse, Eric
• Récher, Christian

Titel

PICALM–MLLT10 acute myeloid leukemia: A French cohort of 18 patients

Ist Teil von

• Leukemia research, 2012-11, Vol.36 (11), p.1365-1369

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract The PICALM–MLLT10 fusion gene, generated by the t(10;11)(p12-13;q14-21) translocation, is a rare but recurrent event in acute leukemias. In this study, we assessed the characteristics and outcome of 18 PICALM–MLLT10 AML patients. As compared with non PICALM–MLLT10 patients ( n = 72), PICALM–MLLT10 AML were characterized by more frequent extramedullary diseases, CD7 expression and higher platelet counts. Three out of four therapy-related PICALM–MLLT10 AMLs had been previously treated for diffuse large B-cell lymphoma. The complete response rate was 71% after intensive chemotherapy. PICALM–MLLT10 patients had a shorter median overall survival than patients with favorable cytogenetics (12 months vs. not reached, p = 0.07) but not significantly different from those of intermediate (26 months, p = 0.32) or unfavorable cytogenetic groups (8 months, p = 0.13). Long term responses were achieved in a subset of patients after allogeneic stem-cell transplantation but also after high-dose cytarabine.